|
JP2005130867A
|
|
Screening assay using calcium in mitochondria
|
|
WO03046225A1
|
|
Mitochondrial dna polymorphisms
|
|
WO02101356A2
|
|
Organellar proteomics including determination of targets for therapeutic intervention identified in the mitochondrial proteome using mass spectrometry
|
|
AU2927102A
|
|
Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
|
|
AU2927302A
|
|
Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
|
|
AU2929002A
|
|
Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
|
|
AU2927602A
|
|
Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
|
|
AU2002254124A1
|
|
Aryl-n-cyanoguanidines and methods related thereto
|
|
US2003026781A1
|
|
Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
|
|
US2002173543A1
|
|
Compounds for altering mitochondrial function and cellular responses
|
|
US2002165216A1
|
|
Cobalt-porphyrin complexes and use thereof as an anti-obesity agent
|
|
AU3953102A
|
|
Differential gene expression in specific regions of the brain in neurodegenerative diseases
|
|
EP1322314A2
|
|
Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter
|
|
AU7684601A
|
|
Methods for identifying mitochondrial divalent cation transporters
|
|
AU6151801A
|
|
Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor
|
|
WO0151923A2
|
|
Screening assays using intramitochondrial calcium
|
|
WO0151922A2
|
|
Identification of peripheral benzodiazepine receptor binding agents
|
|
WO0135096A2
|
|
Diseases associated with altered mitochondrial function
|
|
AU1759901A
|
|
Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes
|
|
AU1351501A
|
|
Gene sequences identified by protein motif database searching
|
